Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
Industry Sector: CommercialServices
CEO: Yue Lei Shen, PhD
Number Of Employees: 1,117
Enterprise Value: $465,446,887
PE Ratio: 145.69
Exchange/Ticker 1: HKEX:2315
Exchange/Ticker 2: N/A
Latest Market Cap: $684,084,158
BioCentury | Mar 4, 2025
Data Byte
Bispecifics overtake ADCs in China deals
Western biopharmas signed more deals for bispecifics than ADCs with China biotechs last year
BioCentury | Aug 6, 2024
Deals
Deals Report: Bispecific space continues to foster partnerships
Plus: Otsuka in $800M takeout of Jnana, BioNTech dropping Genmab’s acasunlimab
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Apr 2, 2024
Deals
Deals report: Abingworth and Blackstone bet on late-stage programs
Plus: Gilead acquires Xilio’s IL-12 program and Harmonic-Turbine to co-develop dark kinase therapy for cancer
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Dec 13, 2023
Emerging Company Profile
Myricx: ADCs with a lipidation inhibitor payload
U.K.-based Myricx is turning a small molecule for parasitic diseases into an ADC payload for cancers
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Apr 13, 2023
Data Byte
Chinese biotechs remain a rich source of ADC deals
Western biotechs have struck at least 10 licensing deals to gain antibody-drug conjugate technology from China since the start of 2022
BioCentury | Feb 28, 2023
Product Development
Feb. 27 Quick Takes: CSL readying HAE submission after garadacimab data
Plus: Chipscreen to commercialize Eucure’s bispecific in China and updates from Reata, SpringWorks
Items per page:
1 - 9 of 9